A Phase Ib, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study To Determine The Maximum Tolerated Dose, Assess The Safety And Tolerability, Pharmacokinetics And Preliminary Efficacy Of Iberdomide CC-220 In Combination With R-CHOP21 And CC-99282 In Combination With R-CHOP21 For Subjects With Previously Untreated, Poor Risk IPI 3-5, Aggressive B-Cell Lymphoma

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT04884035

Study #:
STUDY00148476

Start Date:
Jan 26, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04884035

View Complete Trial Details & Eligibility at ClinicalTrials.gov